184 filings
Page 3 of 10
6-K
5oeiyczd9
5 Aug 22
Current report (foreign)
6:07am
6-K
3an jvb2ji2m7tak9
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
6-K
1s9586c
6 Jul 22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
8:30am
6-K
v1crt4y er9ts
29 Jun 22
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
8:30am
6-K
kbdxmm37bgrdx6j1o
12 May 22
Current report (foreign)
8:30am
6-K
y7vqvs1vk0
28 Apr 22
Current report (foreign)
4:02pm
6-K
jcx7ilf4eke1f84jj4t
7 Apr 22
Current report (foreign)
4:01pm
6-K
bpsdrwc
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
wqeif 6txtlr8wvu
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
bw1ztu3lrc6uk85y
17 Mar 22
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
7:30am
6-K
b078zws8pd 1ybva
8 Mar 22
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
7:51am
6-K
7mqg09
28 Feb 22
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
7:30am
6-K
vnmt3e2gf7m2b
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
j8xxcu004b sm8su
3 Feb 22
Current report (foreign)
4:01pm
6-K
ak66gyr
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
jgm4zc9i 0lk90z5gs2g
5 Jan 22
Current report (foreign)
7:30am
6-K
0bz8p q57lksogq8
15 Nov 21
Current report (foreign)
7:36am
6-K
wx5xa
5 Nov 21
Current report (foreign)
7:30am
6-K
hyq e4xa4v
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am